# Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

> **NCT06017284** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Cancer Stage IV
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06017284
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06017284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06017284, "Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06017284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*